154 related articles for article (PubMed ID: 16651863)
21. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
22. Characterization of an antibody to factor VIII in a patient with acquired hemophilia with circulating immune complexes.
Ly B; Michaelsen TE; Dahl O; Frøland SS
Scand J Haematol; 1982 Feb; 28(2):132-40. PubMed ID: 6806894
[TBL] [Abstract][Full Text] [Related]
23. Studies on human factor VIII and its antibodies using radiolabelling and affinity chromatography.
Kavanagh ML; Wood CN; Davidson JF
Thromb Haemost; 1981 Jun; 45(3):267-71. PubMed ID: 6792739
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
25. Catalytic nucleotide-hydrolyzing antibodies in milk and serum of clinically healthy human mothers.
Semenov DV; Kanyshkova TG; Karotaeva NA; Krasnorutskii MA; Kuznetsova IA; Buneva VN; Nevinsky GA
Med Sci Monit; 2004 Feb; 10(2):BR23-33. PubMed ID: 14737037
[TBL] [Abstract][Full Text] [Related]
26. Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A.
Lacroix-Desmazes S; Misra N; Bayry J; Villard S; Kazatchkine MD; Kaveri SV
J Immunol Methods; 2002 Nov; 269(1-2):251-6. PubMed ID: 12379365
[TBL] [Abstract][Full Text] [Related]
27. Idiotypic regulation of anti-factor VIII antibodies.
Kazatchkine MD; Lacroix-Desmazes S; Moreau A; Kaveri SV
Haematologica; 2000 Oct; 85(10 Suppl):97-9. PubMed ID: 11187885
[TBL] [Abstract][Full Text] [Related]
28. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients.
Nilsson IM; Berntorp E; Zettervall O; Dahlbäck B
Blood; 1990 Jan; 75(2):378-83. PubMed ID: 2104765
[TBL] [Abstract][Full Text] [Related]
29. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
Kallas A; Kuuse S; Maimets T; Pooga M
Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
[TBL] [Abstract][Full Text] [Related]
30. [Circulating anticoagulants against coagulation factors with special reference to anti-factor VIII:C].
Aznar JA
Sangre (Barc); 1985; 30(4-C):813-8. PubMed ID: 3937252
[No Abstract] [Full Text] [Related]
31. [DNA-hydrolyzing IgG antibodies from the blood of patients with acquired immune deficiency syndrome].
Odintsova ES; Kharitonova MA; Baranovskiĭ AG; Siziakina LP; Buneva VN; Nevinskiĭ GA
Mol Biol (Mosk); 2006; 40(5):857-64. PubMed ID: 17086987
[TBL] [Abstract][Full Text] [Related]
32. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
33. [Substrate specificity of serum DNA- and RNA-hydrolyzing antibodies of patients with polyarthritis and autoimmune thyroiditis].
Vlasov AV; Baranovskiĭ AG; Kanyshkova TG; Prints AV; Zabara VG; Naumov VA; Breusov AA; Giege R; Buneva VN; Nevinskiĭ GA
Mol Biol (Mosk); 1998; 32(3):559-69. PubMed ID: 9720080
[No Abstract] [Full Text] [Related]
34. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.
Kessel C; Königs C; Linde R; Escuriola-Ettinghausen C; Stoll H; Klingebiel T; Dietrich U; Kreuz W
Mol Immunol; 2008 Nov; 46(1):8-15. PubMed ID: 18715645
[TBL] [Abstract][Full Text] [Related]
35. Peptides derived from a secretory yeast library restore factor VIII activity in the presence of an inhibitory antibody.
Mersich C; Billes W; Pabinger I; Jungbauer A
Biotechnol Bioeng; 2007 Sep; 98(1):12-21. PubMed ID: 17390380
[TBL] [Abstract][Full Text] [Related]
36. Immunoradiometric assay of factor VIII: coagulant antigen using four human antibodies. Study of 27 cases of haemophilia A.
Girma JP; Lavergne JM; Meyer D; Larrieu MJ
Br J Haematol; 1981 Feb; 47(2):269-82. PubMed ID: 6781526
[TBL] [Abstract][Full Text] [Related]
37. Factor VIII inhibitor with catalytic activity towards factor VIII.
Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Horn MP; Kazatchkine MD; Kaveri SV
Chem Immunol; 2000; 77():102-14. PubMed ID: 11706701
[No Abstract] [Full Text] [Related]
38. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
[TBL] [Abstract][Full Text] [Related]
39. Acquired hemophilia: diagnosis and management.
Zakarija A; Green D
Curr Hematol Rep; 2002 Sep; 1(1):27-33. PubMed ID: 12901122
[TBL] [Abstract][Full Text] [Related]
40. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():37-41; discussion 41-2. PubMed ID: 17123392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
